Differences Between NCI, MSKCC, and UPenn CAR-Modified T Cells
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.
Clinical Pearls
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.
- Only the National Cancer Institute, Memorial Sloan-Kettering Cancer Center (MSKCC), and the University of Pennsylvania (UPenn) have reported significant anti-tumor responses using CAR-modified T cells in B cell malignancies
- It is unknown whether the design of the receptor and the methodology in which the receptor is introduced into the T cell make a clinically meaningful difference
- MSKCC and UPenn are currently conducting a study to evaluate any potential differences in clinical activity
Recent Videos
Related Content
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024Article
In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
